Free radicals in Alzheimer's dementia: currently available therapeutic strategies.
Substantial evidence now exists that oxidative stress may play an important role in the etiopathogenesis of DAT. The different sources of oxidative stress in DAT are suggesting several pharmacological opportunities for influencing the disease. It is possible to distinguish 2 major types of possible therapeutic agents according to their pharmacological point of attack. 1. Radical scavengers, agents directly interacting with free radicals. Candidates of this type are gingko biloba, vitamins A, C, E and estrogen. 2. Antioxidants, which are able to prevent or decrease the production of free radicals by use of specific neuropharmacological properties. Candidates are selegiline, a MAO-B inhibitor well established in the therapy of Parkinson's disease, and tenilsetam, which is believed to be an AGE-inhibitor. Recent in vitro studies have demonstrated the efficacy of both types of therapeutic agents by preventing or delaying oxidative neural damage. Some clinical data exist regarding the antidementive properties particularly in terms of gingko biloba, selegiline and vitamin E. The efficacy studies about these compounds seem to indicate a promising future strategy in the therapy of DAT. But it is too early to draw definite conclusions since it is well known that all of our candidate substances do not act specifically as radical scavengers or antioxidants.
Rösler
M
M
Psychiatric Department, University of Würzburg, Federal Republic of Germany.
Retz
W
W
Thome
J
J
Riederer
P
P
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology* / Q000517:prevention & control; D000975:Antioxidants / Q000627:therapeutic use*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D005609:Free Radicals / Q000378:metabolism; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D010300:Parkinson Disease / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use; D011619:Psychotropic Drugs / Q000627:therapeutic use; D012642:Selegiline / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
D000975:Antioxidants; D004365:Drugs, Chinese Herbal; D016166:Free Radical Scavengers; D005609:Free Radicals; D008996:Monoamine Oxidase Inhibitors; D010879:Piperazines; D011619:Psychotropic Drugs; D013876:Thiophenes; D014815:Vitamins; C080684:cedemin; D012642:Selegiline; C059511:tenilsetam